A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Inclusion Criteria:

1. Body mass index (BMI) ≥ 27 kilograms per meter square (kg/m^2)

2. Previously diagnosed with moderate-to-severe OSA

3. AHI ≥15 events per hour (/hr) prior to Randomization

4. AOBP SBP of ≥130 and less than or equal to (≤) 180 millimeter of mercury (mmHg) andAOBP diastolic blood pressure (DBP) ≥60 and ≤110 mmHg

5. Participants on CPAP or PAP therapy are eligible provided they are on PAP for ≥4hours per night (documented) and for at least 3 months prior to the study enrollment (documented)

6. Participants not currently on PAP therapy, and not anticipated to start PAP for theduration of the study

7. Fertile male and female participants of childbearing potential, and their partners,must agree to use protocol-defined methods of highly effective contraception fromthe Screening Visit until 28 days after the last dose of study drug

Exclusion Criteria:

1. Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit orhistory of diabetic ketoacidosis in the 6 months prior to the Screening Visit

2. Participants on a glucagon-like peptide-1 (GLP-1) agonist.

3. Any surgery for sleep apnea or major ear, nose or throat surgery, includingtonsillectomy and adenoidectomy within 3 months prior to Screening, or plannedduring participation in the study or within 1 month of the last study visit.

4. Have diagnosis of central or mixed sleep apnea with % of mixed or centralapneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration

5. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia

6. Use of bilevel positive airway pressure (BiPAP) therapy.

7. eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2)at Screening using serum creatinine or cystatin-C

8. History of clinically relevant medical, behavioral, or psychiatric disorder, otherthan OSA, that is associated with insomnia or excessive sleepiness

9. Diagnosed with Child-Pugh Class C

10. Participants who regularly use caffeine stimulants or participants who are unwillingto reduce intake to 300 mg per day (approximately 3 cups of coffee), for a period ofat least 3 days prior to the Screening visit or a sleep study

11. Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1month of the Screening Visit

12. Requirement for nocturnal use of supplemental oxygen

13. Women who are pregnant, plan to become pregnant, or are breastfeeding

14. Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6months prior to Screening

15. Previously diagnosed, recurrent orthostatic hypotension

16. Current night-shift worker or anticipated to become a night-shift worker for 3 dayscontinuously during the duration of the study.